Exelixis (EXEL) Peer Comparison

$69.00

up-down-arrow $-0.84 (-1.20%)

As on 13-Nov-2026 16:00EST

Market cap

info icon

$16,837 Mln

Revenue (TTM)

info icon

$2,497 Mln

P/E Ratio

info icon

20.7

P/B Ratio

info icon

9.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Exelixis (EXEL) Ascendis Pharma A/S - ADR Halozyme Therapeutics (HALO) Kymera Therapeutics (KYMR) Madrigal Pharmaceuticals (MDGL)
Market cap ($ Mln)
16,837 18,064 11,432 10,891 9,928
Revenue ($ Mln)
2,497 1,208 1,802 102 1,428
Net Profit ($ Mln)
885.14 890.37 485.42 -349.47 -155.46
Net Margin (%)
35.45 73.69 26.93 -341.87 -10.89
RoE (%)
46.96 88.40 -- -22.16 -26.57
Price to Earnings
20.66 18.11 25.19 -- --
Price-To-Book
9.18 10.44 97.15 6.72 15.76

Income Statement ($ Mln)

Liabilities ($ Mln)

Assets ($ Mln)

Cashflow ($ Mln)

Ratios

Profitability Ratios

Growth Ratios

Valuation Ratios

Solvency Ratios

Operating Efficiency Ratios

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...

Informed fund ideas, better judgment. Every month. Mutual Fund Insight, every month since October 2002.

Take charge. Know more. Keep more. Mutual Fund Insight helps you do all three — every month